uCloudlink Unveils Groundbreaking Innovations at MWC 2025: Redefining Connectivity for IoT, People, and Pets
BARCELONA, Spain, March 3, 2025 /PRNewswire/ -- uCloudlink (NASDAQ: UCL), the world's first and leading mobile data traffic-sharing marketplace, is thrilled to announce its participation in MWC 2025, where it will showcase its latest innovations in connectivity. This year's theme, 'Global First Network: The Ideal Sky-to-Ground Connectivity to Unlock New Revenue – Connecting IoT, People, and Pets,' highlights uCloudlink's transformative solutions for a more connected world.
Revolutionizing Connectivity Across IoT, People, and Pets
uCloudlink's groundbreaking 'Global First Network' concept introduces a seamless sky-to-ground approach to connectivity aimed at transforming the way IoT devices, individuals, and even pets stay connected. By leveraging its proprietary HyperConn®, CloudSIM, and 6-tech Positioning technologies, uCloudlink is breaking barriers in connectivity, creating innovative solutions that enhance digital experiences worldwide.
Key highlights of uCloudlink's vision: Deliver the convenient, secured and premium connectivity among mobile internet, fixed broadband / Wi-Fi and satellite communications with Centralized AI management
IoT Connectivity Solutions: Designed to enhance network coverage and quality with reliable, multi-network support and a well-designed AI management platform. These solutions ensure instant, seamless, and localized connectivity for IoT applications worldwide.
People-Centric Connectivity: With its advanced HyperConn® technology, uCloudlink delivers hyper-local yet global internet access, ensuring users stay connected with high-speed, reliable networks wherever they go, without the limitations of traditional roaming or carrier restrictions.
Pet Connectivity: A revolutionary addition to the digital ecosystem, uCloudlink introduces the PetPhone, the world's first smartphone for pets that brings happiness, safety, health, tracking, and community engagement. The PetPhone allows pet owners to stay close to their furry companions like never before.
These innovations reflect uCloudlink's mission to deliver 'The Ideal Network of Life' through seamless, high-quality connectivity solutions.
Exclusive Product Showcase
PetPhone: Pets Deserve a Smartphone, Just Like You
The PetPhone is the world's first smartphone for pets, enabling true two-way interaction between pets and their families. It features AI-powered live calls, allowing pets to initiate communication through specific actions, 6-tech global positioning for advanced safety, and AI health monitoring to track activity and well-being. Pet owners can also co-create a global community for further engagement. This groundbreaking device redefines the bond between pets and their owners.
eSIM TRIO: A Revolutionary Leap in SIM Technology
The eSIM TRIO combines OTA (Over-the-Air) SIM, eSIM, and CloudSIM technologies in one versatile solution. It ensures seamless global coverage by dynamically connecting to multiple networks, eliminating the need for costly international roaming, and providing users with reliable, high-speed connectivity across devices.
MeowGo G50 Max: Seamless On-The-Go Connectivity Uplifting with Satellite Communication
The MeowGo G50 Max is a next-generation mobile Wi-Fi hotspot powered by HyperConn™ technology. It offers seamless connectivity across broadband, Wi-Fi, 4G, 5G, and satellite networks. With AI-powered network detection and switching, it delivers a convenient and seamless connection experience through centralized management of multiple networks.
CloudSIM Kit
The CloudSIM Kit is a plug-and-play IoT solution delivering instant global full-speed 4G and 5G connectivity for IoT and smart devices. It requires no hardware modifications or software upgrades, making it a simple and effective solution for universal connectivity.
Partnering for New Revenue Opportunities
uCloudlink is committed to building a robust partner network with telecom and technology industry players. By leveraging uCloudlink's innovative technologies, telecom operators can enhance network service quality, expand coverage, and unlock new revenue streams.
'We believe that partnerships are the key to driving innovation and growth in the telecom industry. Together, we can eliminate roaming costs, resolve network congestion, and create seamless connectivity for users globally. Let's build a smarter, safer, and more connected world' said Chaohui Chen, CEO of uCloudlink.
uCloudlink warmly invites attendees to join the new product launch on Show Day 1 at 16:30 – 18:30 in the MWC Networking Hub @Hall 6. The company will also exhibit at Hall 6, Booth #6C73, where live demonstrations of all products will showcase how uCloudlink's innovations are revolutionizing connectivity for IoT, people, and pets.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
11 minutes ago
- Associated Press
Global Times: At Rizhao Port: Small phone screen unlocks code to transform, upgrade China's global trade
BEIJING, June 9, 2025 /PRNewswire/ -- In the sunlit repair depot of Rizhao Port of Shandong Port Group, Xu Guannan stands in front of a giant 17-ton wheel loader. This beast of a machine, capable of lifting 3 cubic meters of coals in one scoop, is not humming well these days, sending its work efficiency down. Initial reports suggest the machine is hit by overheating problems, but dozens of parts could be the culprit. A traditional repair work would by this time start climbing this behemoth and try to scout for faulty parts, guided by hunches and experience. Instead, Xu, deputy head of the Technology Innovation Center of Rizhao Port, reached into his pocket to grab his smartphone. From the small screen, Xu accessed the interface of a digital repair manual developed by his team of software engineers and powered by the latest artificial intelligence (AI) tool DeepSeek, which analyzed the problem in a flash and gave the answer - a ventilation valve on the gearbox is at fault. This is just a snapshot of the high-tech-powered, smart operation of Rizhao Port, which has earned the highest praise for its successful transformation and upgrade over the years. On the afternoon of May 22, 2024, Xi Jinping, general secretary of the Communist Party of China Central Committee, Chinese president and chairman of the Central Military Commission, visited Rizhao Port, the Xinhua News Agency reported at the time. Xi said that Rizhao Port, as a new port after China's reform and opening-up drive, has transformed itself from a traditional port into a modern one through scientific and technological innovation in recent years. It has not only made the cargo throughput among the forefront of the country, but also accumulated experience in developing new quality productive forces through the transformation and upgrading of traditional industries, which is worthy of praise, Xi said, according to Xinhua. Currently, as global trade has encountered profound turbulence due to rising unilateralism and protectionism in certain parts of the world, China's focus on building modern ports and developing new quality productive forces underscore its unwavering commitment not only to high-quality development at home, but also to mutually beneficial trade with the rest of the world. This is also the underlying logic of China's development of the port economy: Let the world share China's opportunities. China is committed to building world-class ports to expand its 'circle of friends' of trading partners, contributing to the stability of global supply chains. 'Chinese model' Such a commitment translates into real action at Rizhao Port: autonomous trucks glide across the docks, guided by AI precision; Towering cranes, controlled remotely from a sleek command center, dance in perfect sync, unloading megaships with balletic grace. Behind this futuristic symphony of machines working seamlessly together are years of dedicated efforts to transform this once modest port into a high-tech titan, earning accolades as a 'Chinese model' for the transformation and upgrading of traditional terminals into fully automated container terminals worldwide. For Xu and his team, that means harnessing the country's latest technological advancements to empower the port's operation. Since last year, Xu's team sorted out and compiled a total of 400,000 paper maintenance log entries in the past 10 years for the port's dozens of wheel loaders and made all the information digitalized into a knowledge graph. 'In a way, we perpetuated old repair masters' wisdom through digitalization and AI,' Xu told the Global Times. The adoption of large language model is just one facets of the port's efforts in harnessing the hardcore power of technology to empower the port's smart operations. Tian Zhendong, a first-grade technician at the Technology Innovation Center of Rizhao Port of Shandong Port Group and a holder of the National May 1 Labor Medal, works at the port's 100-million-ton dry bulk cargo terminal. The terminal handles the transportation and storage of over 70 types of cargo across five major categories. Following recent technological upgrades, it is now home to over 80 sets of automated equipment across 10 major categories and operators control these machines from an office building located thousand meters away. In addition to remotely control portal cranes, a total of 24 industrial robots were employed to do the heavy and dirty job of cleaning coal-carrying rail cars and removing sticky coke. This solution alone has greatly improved unloading efficiency and slashed labor cost by 70 percent, Tian said. 'Our attitude toward automation is: once it's installed, we must use it. If we don't use it, we can't discover problems to help improve the system, and we can't truly enjoy the high efficiency automation brings,' Tian told the Global Times. Such a devotion from Tian and other workers at the port helped build the world's first parallel, open and fully automated container terminal, which handles about 6 million TEUs a year with dozens of operator-less ship-to-shore (STS) container cranes and automated guided vehicles (AGVs) working in harmony around-the-clock. The automation resulted in a single machine efficiency boost by 50 percent and reduction in overall cost by 70 percent, according to Rizhao Port authorities. Green development Smart operation is just one aspect of Rizhao Port's transformation witnessed by Tian, who started working at the port in 1989 and a second-generation port worker. His father participated in the construction of Rizhao Port in the 1980s, witnessing the port's transformation from a small fishing village on the East China Sea coast into a major coal port in China. 'In the past, city residents who live nearby the port area can tell the main cargo being transported in the port in a given period by the color of the powder dust clinging on their windows - red is iron and black is coal,' Tian said. One defining moment of the port's history, Tian recalled, is a State Council guideline policy in 2022 stipulating support for Rizhao Port to become a smart and green demonstration port for bulk dry cargo. 'With the emphasis on ecological protection in the past decade and dedicated efforts in greening the port's operation area, we have a cleaner port and a cleaner city nowadays,' Tian said, 'The theme color of Rizhao Port's story has changed from one of red and black to one featuring green and blue.' Ultimately, efforts to ensure smart and green operations are aimed at bolstering Rizhao Port's core function of handling cargoes. And in that regard, the port has also seen remarkable achievements: the port is the world's youngest port achieving an annual throughput of 500 million tons; it ranks first in China in the throughput of seven types of goods, including iron ore, soybeans, petroleum and coke; and it has become a vital port supplying raw materials and bulk commodities to the 'World's Factory.' Powering exports During the visit to Rizhao Port in May 2024, Xi learned about the local progress in promoting the smart and green development of the port, and expanding the opening-up, according to Xinhua. Rizhao Port's transformation is aimed at not only supporting the country's high-quality development, but also promoting high-level opening-up. The point of having a world-class port lies in serving world-class trade, as some workers at Rizhao Port told the Global Times. In recent years, companies in and around Rizhao city have seized the opportunity to advance port-industry-city integration and leveraged the port's shipping links with more than 100 countries and regions. Rizhao Port served as a vital link efficiently bridging production resources with global demand and effectively facilitating the global expansion of more 'Made in China' products. Wuzheng Group, a major player in China's agricultural and commercial vehicle industry located in the nearby Wulian county, offers a prime example. Rizhao Port's advantages in land transportation, efficiency, and marine transportation costs have provided the company with efficient, economical, and reliable logistics services, giving its overseas businesses a high-quality boost, according to Liang Yong, head of the company's international cooperation department. 'A three-wheeled vehicle, great at traversing inferior roads, is produced every three minutes on average at our plant and most are sold overseas to countries in Africa, including Ghana, Burkina Faso and Tanzania,' Liang Yong, head of the company's international cooperation department, told the Global Times. In May, Wuzheng Group exported 1,000 diesel-powered tricycles customized for West African mining areas through Rizhao Port, setting a new record for a single shipment of Chinese diesel tricycles to Africa. Behind that number is real stories of how 'Made in China' products changing lives in countries and regions. Liang said that many African customers told him how the three-wheeled vehicles changed their lives and help them pursue better a life. Wuzheng Group is hardly alone in leveraging the advantages offered by Rizhao Port to expand exports. Rizhao Yulan Intelligent Manufacturing Industrial Park, which is located just 15 kilometers from the port area, is also one of the companies utilizing the resources brought by the Rizhao Port. The company's highly automated plant transforms steel rolls into tinplate, a premium product having great overseas demand for its use in the making of cans used for storing fast-moving consumer goods like infant formula and beverages. 'Most of Shandong's steel production occurs near Rizhao, where our facility is based,' Wang Dawei, deputy general manager of Rizhao Yulan New Materials Co, 'This grants us access to low-cost raw materials. At the same time, we benefit from the port's extensive shipping routes, facilitating our global exports.' With over 80 container shipping routes from Rizhao and over 360 shipping routes of Shandong Port Group, Rizhao Port is a major node in the New Eurasian Land Bridge Economic Corridor as well as an important link of the Belt and Road Initiative. In addition to more destinations of exports, the types of goods shipped from Rizhao have also expanded to include new products such as new-energy vehicles (NEVs). In March, a batch of NEVs from Rizhao Port were officially shipped, marking a leap in the port's business related to the 'new three' of China's tech-intensive and green exports - NEVs, photovoltaic products, and lithium batteries, according to local media reports. The development story of Rizhao Port provides a footnote for China's steadfast efforts to strengthen its connection and exchanges with the rest of the world despite rising unilateralism and protectionism. Building world-class ports is one major aspect of those efforts, and China has made great strides - China is now home to eight of the world's top 10 busiest ports in terms of cargo throughput and seven of the world's top 10 ports in terms of container throughput, data from the Ministry of Transport showed. 'Port serves trade, and automation can make a port better. It is precisely this pragmatic attitude toward technological transformation that has enabled us to achieve what we have done so far and empowers our pursuit of a better tomorrow,' Xu said. View original content: SOURCE Global Times
Business Wire
25 minutes ago
- Business Wire
Alnylam Receives European Commission Approval for AMVUTTRA ® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA ® (vutrisiran). The approval broadens the indication for AMVUTTRA, which now becomes the first and only RNAi therapeutic approved by the EC for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of hereditary transthyretin-mediated amyloidosis (hATTR) in adults. Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy Share 'Estimates show approximately 100,000 people are affected by ATTR amyloidosis across Europe, most with cardiomyopathy, so this approval marks a critical step toward addressing this underserved patient population,' said Pushkal Garg, M.D., Chief Medical Officer at Alnylam. 'AMVUTTRA is supported by a well-established efficacy and safety profile, with over 6,000 patient-years of global experience in the treatment of hATTR with polyneuropathy. By delivering rapid and sustained knockdown of TTR through convenient, quarterly dosing, it offers a clinically differentiated approach with the potential to transform outcomes for patients living with this debilitating and potentially fatal disease. We now look forward to securing access to AMVUTTRA for eligible patients across the EU as quickly as possible.' The EC decision is based on positive results from the pivotal HELIOS-B Phase 3 study – a randomized, double-blind, placebo-controlled, multicenter, global trial that enrolled a diverse group of patients reflective of the contemporary ATTR-CM population, including those receiving substantial concurrent use of available standard-of-care therapies such as tafamidis and SGLT2 inhibitors. AMVUTTRA met all 10 pre-specified primary and secondary endpoints across both the overall and monotherapy populations. These included statistically significant reductions in all-cause mortality and recurrent cardiovascular events, as well as significant improvements in functional capacity (6-minute walk test), health status and quality of life (Kansas City Cardiomyopathy Questionnaire), and heart failure symptoms and severity (NYHA class). In the overall population, AMVUTTRA achieved a 28% reduction in the primary composite of all-cause mortality and recurrent cardiovascular events as compared to placebo. Mortality in this population was significantly reduced by 36% through 42 months in a pre-specified secondary endpoint analysis which included up to 36 months of the double-blind period plus six months of open-label extension. In HELIOS-B, rates of adverse events (AEs), serious AEs, severe AEs and AEs leading to study drug discontinuation were similar between the AMVUTTRA and placebo arms. Adverse drug reactions of AMVUTTRA include injection site reactions and increase in blood alkaline phosphatase and alanine transaminase. Detailed results from the HELIOS-B study were published in The New England Journal of Medicine. 1 'The HELIOS-B findings provide compelling evidence to support the use of vutrisiran as a first-line treatment option for patients with ATTR-CM,' said Marianna Fontana, M.D., Ph.D., HELIOS-B investigator, Professor of Cardiology, University College London, National Amyloidosis Center, Royal Free Hospital, London. 'As a physician, it is a privilege to see the true impact on patients in the clinic. The trial enrolled a broad population reflective of real-world clinical practice, and that's what makes the results so meaningful. This is a milestone for patients, who now have a new treatment option that has the potential to significantly improve outcomes of this disease.' ATTR-CM is caused by the deposition of misfolded TTR fibrils, which drive progressive and irreversible cardiovascular damage and premature death. AMVUTTRA is an RNAi therapeutic that works upstream by delivering sustained knockdown of disease-causing TTR at its source. In the EU, it is administered as a subcutaneous injection once every three months, either by a healthcare professional, or self-administered by patients or their caregivers, offering flexibility in treatment delivery. 'Amyloidosis is a serious and progressive disease that significantly impacts not only patients' physical health, but also their quality of life and independence. I am thrilled by the news of a new therapy for people in the EU living with ATTR-CM who often face delayed diagnosis. Having a new treatment option available marks a welcome development for the amyloidosis community,' said Giovanni d'Alessio, President of the Amyloidosis Alliance. In May 2025, the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on the maintenance of the EU Orphan Designation for AMVUTTRA in ATTR amyloidosis. AMVUTTRA was approved in March 2025 by the U.S. Food and Drug Administration (FDA) and the Brazilian Health Regulatory Agency (ANVISA) for the treatment of the cardiomyopathy of wild-type or hereditary ATTR amyloidosis in adults. Alnylam continues to pursue additional global submissions to bring vutrisiran to patients worldwide. Indications In the EU, AMVUTTRA ® (vutrisiran) is indicated for the treatment of: hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN). wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Important Safety Information Reduced Serum Vitamin A Levels and Recommended Supplementation Vutrisiran treatment leads to a decrease in serum vitamin A levels. Supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients taking vutrisiran. Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness). Adverse Reactions Commonly reported adverse reactions with vutrisiran were injection site reactions and increase in blood alkaline phosphatase and alanine transaminase. For additional information about vutrisiran, please see the full Summary of Product Characteristics. About AMVUTTRA ® (vutrisiran) AMVUTTRA ® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of variant and wild‑type transthyretin (TTR), addressing the underlying cause of transthyretin (ATTR) amyloidosis. Administered quarterly via subcutaneous injection, vutrisiran is approved and marketed in more than 15 countries for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. It is also approved in the U.S. and Brazil for the treatment of wild-type or hereditary ATTR amyloidosis in adult patients with cardiomyopathy (ATTR-CM). In the EU, AMVUTTRA is administered once every three months, either by a healthcare professional or through self-administration by patients or their caregivers. About ATTR Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating and fatal disease caused by misfolded transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant and affects approximately 50,000 people worldwide, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant and impacts an estimated 200,000-300,000 people worldwide. 2-5 About RNAi RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. 6 Its discovery has been heralded as 'a major scientific breakthrough that happens once every decade or so,' and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. 7 By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors that encode for disease-causing or disease pathway proteins – thus preventing them from being made. 6 This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its ' Alnylam P 5 x25 ' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. Alnylam Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam's expectations, beliefs, goals, plans or prospects including, without limitation, Alnylam's expectations regarding the safety and efficacy of AMVUTTRA for the treatment of ATTR-CM; the potential for AMVUTTRA to be used as a first-line treatment for ATTR-CM; the potential for AMVUTTRA to address the underserved ATTR-CM patient population and to improve outcomes for ATTR-CM patients; and Alnylam's ability to secure access to AMVUTTRA for eligible patients across the EU and the timing of such access should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam's ability to successfully execute on its ' Alnylam P 5 x25 ' strategy; Alnylam's ability to successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam's product candidates; actions or advice of regulatory agencies and Alnylam's ability to obtain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam's approved products globally; and any delays, interruptions or failures in the manufacture and supply of Alnylam's product candidates or its marketed products; as well as those risks more fully discussed in the 'Risk Factors' filed with Alnylam's 2024 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam's subsequent Quarterly Reports on Form 10-Q and in its other SEC filings. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
Yahoo
28 minutes ago
- Yahoo
Got $1,000? Super Micro Computer Stock Is a Brilliant Backdoor AI Play
Super Micro Computer's DLC technology offers huge cost savings for companies constructing data centers. Supermicro faces some headwinds due to tariffs. Supermico's stock looks cheap compared to many other AI players. 10 stocks we like better than Super Micro Computer › There are many ways to play the AI investment trend. Hardware companies like Nvidia (NASDAQ: NVDA) are powering the training of AI models, suppliers like Taiwan Semiconductor (NYSE: TSM) are building the chips for Nvidia, and software companies like Palantir (NASDAQ: PLTR) are providing platforms to deploy AI for real-world use. I tend to prefer neutral options in the AI space. That way, I can benefit from the general buildout of AI rather than having one company succeed. While Nvidia is an excellent choice in this realm, so is Super Micro Computer (NASDAQ: SMCI). Super Micro Computer, often called Supermicro, builds server racks and cooling solutions for data centers to house high-powered computing devices like Nvidia's GPUs. Supermicro has seen impressive growth over the past few years, but what's ahead could make investors even more money. Server racks are fairly commoditized, so there isn't much to separate one competitor from another. However, one area where a company can make a name for itself is customizability and cooling technology. Supermicro's racks are highly modular, allowing clients of all sizes to find a server rack that fits their workload size and application. Another advantage of Supermicro's solutions is its direct liquid-cooling (DLC) technology. Traditionally, computing hardware is cooled by moving air across the unit, which isn't the most efficient way to cool these units. Supermicro's DLC technology moves liquid across the surface (contained in tubes), which is a far more efficient way to cool them. Furthermore, because these units don't have to account for airflow, Supermicro's clients can pack more server racks into a given space, which helps decrease building costs. Supermicro estimates that this provides up to 40% energy savings and 80% space savings. Supermicro also has key partnerships in the industry, most notably with Nvidia. Nvidia's most powerful chip, based on Blackwell architecture, can be placed in servers purpose-built to hold those exact GPUs, helping users squeeze out every last bit of performance from these chips. In Supermicro's third quarter of fiscal year 2025 (ended March 31), sales rose 19% year over year to $4.6 billion. While that's solid growth, the company faces some headwinds due to tariffs. Supermicro also faces some headwinds moving into next quarter, with revenue expected to be about $6 billion at the midpoint of guidance, indicating 13% growth. However, one area where Supermicro shines is its valuation, as shares can be scooped up for a dirt-cheap level. Supermicro's stock trades for just 15.2 times fiscal year 2026's earnings, which is far cheaper than most of the AI stocks in the market, which commonly trade in the high-20s to the low-30s range. As Supermicro figures out tariffs and shifts supply chains around, it could see its growth start to reaccelerate, as AI demand is still massive. Nvidia forecast, using third-party data, that data center capital expenditures would reach $400 billion in 2024 but could rise to $1 trillion by 2028. Should this occur, Supermicro will see its business rapidly expand due to the field in which it's playing. That kind of growth could send Supermicro's stock soaring if it can capture the bulk of server infrastructure, making Supermicro a potentially fantastic buy to capitalize on the AI arms race that's still heating up. Before you buy stock in Super Micro Computer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Super Micro Computer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Keithen Drury has positions in Nvidia and Taiwan Semiconductor Manufacturing. The Motley Fool has positions in and recommends Nvidia, Palantir Technologies, and Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy. Got $1,000? Super Micro Computer Stock Is a Brilliant Backdoor AI Play was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
